DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

Xolair (Omalizumab) - Side Effects and Adverse Reactions

 
 



ADVERSE REACTIONS

The most serious adverse reactions occurring in clinical studies with Xolair are malignancies and anaphylaxis (see WARNINGS). The observed incidence of malignancy among Xolair-treated patients (0.5%) was numerically higher than among patients in control groups (0.2%). Anaphylactic reactions were rare but temporally associated with Xolair administration.

The adverse reactions most commonly observed among patients treated with Xolair included injection site reaction (45%), viral infections (23%), upper respiratory tract infection (20%), sinusitis (16%), headache (15%), and pharyngitis (11%). These events were observed at similar rates in Xolair-treated patients and control patients. These were also the most frequently reported adverse reactions resulting in clinical intervention (e.g., discontinuation of Xolair, or the need for concomitant medication to treat an adverse reaction).

Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of one drug cannot be directly compared with rates in the clinical trials of another drug and may not reflect the rates observed in medical practice.

The data described above reflect Xolair exposure for 2076 adult and adolescent patients ages 12 and older, including 1687 patients exposed for six months and 555 exposed for one year or more, in either placebo-controlled or other controlled asthma studies. The mean age of patients receiving Xolair was 42 years, with 134 patients 65 years of age or older; 60% were women, and 85% Caucasian. Patients received Xolair 150 to 375 mg every 2 or 4 weeks or, for patients assigned to control groups, standard therapy with or without a placebo.

Table 4 shows adverse events that occurred >/= 1% more frequently in patients receiving Xolair than in those receiving placebo in the placebo-controlled asthma studies. Adverse events were classified using preferred terms from the International Medical Nomenclature (IMN) dictionary. Injection site reactions were recorded separately from the reporting of other adverse events and are described following Table 4.

Table 4
Adverse Events >/=1% More Frequent in Xolair-Treated
Patients
Adverse event Xolair
n=738
(%)
Placebo
n=717
(%)
Body as a whole    
   Pain 7 5
   Fatigue 3 2
Musculoskeletal system    
   Arthralgia 8 6
   Fracture 2 1
   Leg pain 4 2
   Arm pain 2 1
Nervous system    
   Dizziness 3 2
Skin and appendages    
   Pruritus 2 1
   Dermatitis 2 1
Special senses    
   Earache 2 1

Age (among patients under age 65), race, and gender did not appear to affect the between group differences in the rates of adverse events.

INJECTION SITE REACTIONS

Injection site reactions of any severity occurred at a rate of 45% in Xolair-treated patients compared with 43% in placebo-treated patients. The types of injection site reactions included: bruising, redness, warmth, burning, stinging, itching, hive formation, pain, indurations, mass, and inflammation.

Severe injection-site reactions occurred more frequently in Xolair-treated patients compared with patients in the placebo group (12% versus 9%).

The majority of injection site reactions occurred within 1 hour-post injection, lasted less than 8 days, and generally decreased in frequency at subsequent dosing visits.

IMMUNOGENICITY

Low titers of antibodies to Xolair were detected in approximately 1 / 1723 (<0.1%) of patients treated with Xolair. The data reflect the percentage of patients whose test results were considered positive for antibodies to Xolair in an ELISA assay and are highly dependent on the sensitivity and specificity of the assay. Additionally, the observed incidence of antibody positivity in the assay may be influenced by several factors including sample handling, timing of sample collection, concomitant medications, and underlying disease. Therefore, comparison of the incidence of antibodies to Xolair with the incidence of antibodies to other products may be misleading.

Allergic symptoms, including urticaria, dermatitis, and pruritus were observed in patients treated with Xolair. There were also 3 cases of anaphylaxis observed within 2 hours of Xolair administration in which there were no other identifiable allergic triggers (see WARNINGS: Anaphylaxis).



REPORTS OF SUSPECTED XOLAIR SIDE EFFECTS / ADVERSE REACTIONS

Below is a sample of reports where side effects / adverse reactions may be related to Xolair. The information is not vetted and should not be considered as verified clinical evidence.

Possible Xolair side effects / adverse reactions in 48 year old female

Reported by a consumer/non-health professional from Brazil on 2011-10-11

Patient: 48 year old female

Reactions: Incorrect Route of Drug Administration, Asthma, Nasopharyngitis, Injection Site Haemorrhage, Cough

Adverse event resulted in: hospitalization

Suspect drug(s):
Xolair

Other drugs received by patient: Spiriva; Seretide; Fluoxin



Possible Xolair side effects / adverse reactions in 57 year old female

Reported by a health professional (non-physician/pharmacist) from United States on 2011-10-13

Patient: 57 year old female

Reactions: Dyspnoea

Suspect drug(s):
Xolair



Possible Xolair side effects / adverse reactions in 33 year old female

Reported by a physician from Belgium on 2011-10-14

Patient: 33 year old female

Reactions: Asthma, Pruritus, Injection Site Pain

Suspect drug(s):
Xolair
    Dosage: 2 df, q2w
    Indication: Asthma

Xolair

Other drugs received by patient: Beta-2 Agonist NOS



See index of all Xolair side effect reports >>

Drug label data at the top of this Page last updated: 2006-09-01

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017